A phase I/II trial of an encapsulated cell therapy product [NovaCaps] for advanced, inoperable pancreatic cancer

Trial Profile

A phase I/II trial of an encapsulated cell therapy product [NovaCaps] for advanced, inoperable pancreatic cancer

Completed
Phase of Trial: Phase I/II

Latest Information Update: 25 Apr 2016

At a glance

  • Drugs Microencapsulated CYP2B1-expressing cells PharmaCyte Biotech (Primary) ; Ifosfamide
  • Indications Pancreatic cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 25 Apr 2016 Results published in the PharmaCyte Biotech Media Release
    • 21 Jul 2015 Results published in PharmaCyte Biotech media release.
    • 10 Jun 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top